OCE-205 Emerging Drug Insight

“OCE-205 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about OCE-205 for Acute Kidney Injury (AKI) in the seven major markets. A detailed picture of the OCE-205 for AKI in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the OCE-205  for AKI. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OCE-205 market forecast analysis for AKI in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in AKI.

Drug Summary

Ocelot Bio’s lead asset, OCE-205, is a therapeutic peptide with a differentiated profile that has demonstrated potential for improving outcomes for patients with End-Stage Liver Disease (ESLD) complications.

The company is exploring the clinical development of OCE-205 in hepatorenal syndrome with AKI. It offers promise for reversing renal failure and prolonging survival to enable more patients to successfully undergo liver transplantation with fewer needing combined liver and kidney transplantation. HRS-AKI is a serious and rapidly progressive complication of ESLD that may occur in patients with advanced liver disease and results from inadequate renal perfusion and intense renal vasoconstriction. While initially reversible, it can lead to irreversible renal failure if inadequately treated.

OCE-205’s innovation emanates from its design as a mixed agonist-antagonist peptide selective for the Vasopressin 1a (V1a) receptor with no vasopressin 2 (V2) receptor activity at drug concentrations achieved while treating ESLD. Under its mixed V1a agonist/antagonist activity, the OCE-205 treatment relieves portal hypertension while offering a capped maximal efficacy that avoids excessive vasoconstriction seen with full agonists, which may lead to ischemic events. By eliminating V2 activity, OCE-205 treatment potentially avoids fluid retention and overload. Under its submaximal agonism and selectivity, OCE-205 harnesses a proven mechanism of action for treating HRS-AKI while addressing existing agents’ limitations.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the OCE-205 description, mechanism of action, dosage and administration, research and development activities in AKI.
• Elaborated details on OCE-205 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OCE-205 research and development activities in AKI across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around OCE-205.
• The report contains forecasted sales of for AKI till 2032.
• Comprehensive coverage of the late-stage emerging therapies for AKI.
• The report also features the SWOT analysis with analyst views for OCE-205 in AKI.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OCE-205 Analytical Perspective by DelveInsight

In-depth OCE-205  Market Assessment

This report provides a detailed market assessment of OCE-205 for AKI in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

OCE-205  Clinical Assessment

The report provides the clinical trials information of OCE-205 for AKI covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for AKI is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OCE-205 dominance.
• Other emerging products for AKI are expected to give tough market competition to OCE-205 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OCE-205 in AKI.
• Our in-depth analysis of the forecasted sales data of OCE-205 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OCE-205 in AKI.

Key Questions

• What is the product type, route of administration and mechanism of action of OCE-205?
• What is the clinical trial status of the study related to OCE-205 in AKI and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OCE-205 development?
• What are the key designations that have been granted to OCE-205 for AKI?
• What is the forecasted market scenario of OCE-205 for AKI?
• What are the forecasted sales of OCE-205 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to OCE-205 for AKI?
• Which are the late-stage emerging therapies under development for the treatment of AKI?